The federal lifespan-testing program just took two famous compounds off the shelf: berberine and CBD

The ITP, running since 2002, is deliberately unforgiving: it accepts up to six interventions a year, tests them identically at three independent sites, and publishes results whether or not the compound works — it has found 15 individual agents and two combinations that significantly increased median lifespan, and many more that did not. Selection for pilot testing is not a result; it is admission to the exam.

What happens in the pilot stage?

Pilot work asks practical gating questions first: is the compound stable when mixed into mouse food, is it absorbed into the bloodstream, and is it toxic at candidate doses? Hensley remains involved as sponsor, collaborating on study design and interpretation and co-authoring resulting publications. Only compounds that clear the pilot advance to Stage I lifespan testing in genetically diverse mice, where survival — not a biomarker — is the endpoint.

Why does berberine's mitochondrial angle make it a serious candidate?

Berberine influences cellular energy metabolism through AMPK activation and mild complex I inhibition — a hormetic, mitochondria-centered mechanism in the same family as metformin's. That gives it a coherent biological rationale for an aging intervention, which is exactly what the ITP exists to test rather than assume. CBD's rationale rests more on inflammation and stress-response pathways; the program will judge both by the same survival standard.

What should supplement buyers take from this?

Perspective, in both directions. Two heavily marketed compounds are finally entering a testing pipeline capable of settling whether they extend lifespan in mammals — and until that pipeline reports, every lifespan claim made for either one is ahead of the evidence. Selection is the start of the test, not the passing grade.

Where the evidence stands

• Established: The NIA Interventions Testing Program (since 2002) is the reference standard for lifespan claims in mice: multi-site, genetically diverse animals, published null results; berberine acts on AMPK/complex I energy pathways in preclinical models.
• Preliminary: Per Southern Illinois University's October 13, 2026 announcement, berberine and CBD (proposed by Lisa Hensley) were selected for ITP pilot testing — stability, absorption and toxicity screening ahead of any Stage I lifespan study.
• Absent: Any lifespan result for berberine or CBD, and any human evidence that either extends life or healthspan.